Display options
Share it on

Pulm Circ. 2018 Jan-Mar;8(1):2045893217743616. doi: 10.1177/2045893217743616. Epub 2017 Nov 03.

Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies.

Pulmonary circulation

Duncan Grady, Marjorie Weiss, Jules Hernandez-Sanchez, Joanna Pepke-Zaba

Affiliations

  1. 1 2144 Pharmacy Department, Papworth Hospital NHS Foundation Trust , Papworth Everard, UK.
  2. 2 2112 Department of Pharmacy and Pharmacology, University of Bath , Bath, UK.
  3. 3 2144 Papworth Trials Unit Collaboration, Papworth Hospital NHS Foundation Trust , Papworth Everard, UK.
  4. 4 2144 Pulmonary Vascular Disease Unit, Papworth Hospital NHS Foundation Trust , Papworth Everard, UK.

PMID: 29099657 PMCID: PMC5731720 DOI: 10.1177/2045893217743616

Abstract

The aims of this study were to investigate the medication adherence of patients on pulmonary hypertension (PH)-targeted therapies and uncover factors that might influence adherence values. Patients taking at least one specialist medicine (sildenafil, tadalafil, bosentan, ambrisentan, iloprost, epoprostenol, treprostinil) completed a Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire. Participants' MMAS-8 scores were used to estimate overall medicine adherence. Potential adherence co-factor data were collected from patient databases and hospital discharge summaries. The MMAS-8 questionnaire was completed by 263 patients (mean age = 61.6 ± 14.8 years, 70.6% women). Data from MMAS-8 showed that 47.9% reported high adherence, 40.3% moderate adherence, and 11.8% low adherence. Factors associated with adherence as measured by the MMAS-8 included: older age; taking monotherapy; and having a higher number of co-morbidities or concurrent medicines. Higher administration frequency, greater length of time on targeted therapy, and use of a compliance aid had a negative association with adherence. Overall adherence to PH specialist medicines is relatively high but a proportion of patients report sub-optimal adherence behavior. A number of factors may help to recognize susceptible patients.

Keywords: MMAS-8; Morisky; compliance; concordance; medicines

References

  1. Am J Manag Care. 2015 Jun;21(8 Suppl):s151-61 - PubMed
  2. Am J Manag Care. 2009 Jan;15(1):59-66 - PubMed
  3. Front Pharmacol. 2013 Jul 25;4:91 - PubMed
  4. BMJ Open. 2014 May 16;4(5):e004735 - PubMed
  5. J Med Econ. 2013;16(2):298-306 - PubMed
  6. Diabetes Res Clin Pract. 2015 Nov;110(2):129-36 - PubMed
  7. N Engl J Med. 2005 Aug 4;353(5):487-97 - PubMed
  8. Eur J Public Health. 2016 Feb;26(1):48-52 - PubMed
  9. J Clin Hypertens (Greenwich). 2008 May;10(5):348-54 - PubMed
  10. N Engl J Med. 2004 Sep 30;351(14):1425-36 - PubMed
  11. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD000011 - PubMed
  12. Can J Diabetes. 2016 Feb;40(1):58-65 - PubMed
  13. BMC Med Res Methodol. 2011 Nov 03;11:149 - PubMed
  14. Nurs Clin North Am. 2008 Mar;43(1):133-53; vii-viii - PubMed
  15. J Am Soc Hypertens. 2015 Jun;9(6):420-426.e2 - PubMed
  16. Int J Cardiol. 2014 Dec 15;177(2):477-82 - PubMed
  17. Value Health. 2009 Jan-Feb;12(1):118-23 - PubMed
  18. Clin Med Res. 2013 Jun;11(2):54-65 - PubMed
  19. Br J Clin Pharmacol. 2012 May;73(5):691-705 - PubMed
  20. Ann Intern Med. 1991 Sep 1;115(5):343-9 - PubMed

Publication Types